早期肝外胆管癌:胆管切除与胰十二指肠切除术的安全性与长期结局比较
该回顾性研究比较了早期肝外胆管癌(Tis-T2且N0)患者行肝外胆管切除(n=34)与胰十二指肠切除术(n=75)的结局。胆管切除虽并发症更少、住院更短,但5年总生存(38.9% vs 60.4%)和无复发生存(31.7% vs 57.4%)均显著更差(均P<.01)。结论认为胰十二指肠切除术应作为可耐受者的标准术式。
要点
- 肝外胆管切除术后主要并发症更低(5.9% vs 45.3%),住院更短(11 vs 25天)。
- 胆管切除的5年总生存和无复发生存均显著劣于胰十二指肠切除术(均P<.01)。
- 在切缘阴性患者中,胆管切除仍与更高的局部复发相关(38.1% vs 11.6%,P<.01)。
核心结论
- 尽管肝外胆管切除围手术期并发症更低,但其肿瘤学结局劣于胰十二指肠切除术,即使在早期肝外胆管癌中也是如此。
- 胰十二指肠切除术应被视为可耐受患者的标准手术方式。
- 肝外胆管切除不应被视为与胰十二指肠切除术肿瘤学等效,但对于无法耐受胰十二指肠切除术的精选患者仍可作为一种治疗选择。
研究设计与样本
- 回顾性研究,纳入2009年至2024年间接受肝外胆管切除或胰十二指肠切除术的患者。
- 排除远处转移或术前化疗者,共分析109例早期(Tis-T2且N0)患者:胆管切除34例,胰十二指肠切除75例。
- 采用Kaplan-Meier法和Cox比例风险模型进行生存分析。
主要发现
- 胆管切除组主要并发症发生率为5.9%,胰十二指肠切除组为45.3%(P<.01)。
- 胆管切除组住院时间为11天,胰十二指肠切除组为25天(P<.01)。
- 胆管切除组5年总生存率为38.9%,胰十二指肠切除组为60.4%;5年无复发生存率分别为31.7%和57.4%(均P<.01)。
- 多因素分析显示,肝外胆管切除和T2分期是总生存和无复发生存不良的独立预测因素。
- 在切缘阴性患者中,胆管切除组5年总生存率为51.2% vs 61.6%(P=.051),无复发生存率为37.3% vs 59.9%(P=.022),局部复发率为38.1% vs 11.6%(P<.01)。
临床怎么用
- 对于可耐受手术的早期肝外胆管癌患者,应优先考虑胰十二指肠切除术以改善肿瘤学结局。
- 肝外胆管切除可作为无法耐受胰十二指肠切除术的精选患者的替代方案,但需告知其肿瘤学劣势。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- 样本量较小(共109例),胆管切除组仅34例。
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extrahepatic bile duct resection has been proposed as a less invasive alternative to pancreaticoduodenectomy for selected patients with extrahepatic cholangiocarcinoma. However, its oncological validity in early stage disease remains unclear. This study compared short- and long-term outcomes of extrahepatic bile duct resection and pancreaticoduodenectomy in early stage extrahepatic cholangiocarcinoma. METHODS: Patients who underwent extrahepatic bile duct resection or pancreaticoduodenectomy between 2009 and 2024 were retrospectively reviewed. Patients with distant metastasis or preoperative chemotherapy were excluded. Clinicopathologic characteristics, postoperative outcomes, recurrence-free survival, and overall survival were compared in patients with early stage disease (Tis-T2 and N0). Survival analyses were performed using Kaplan-Meier and Cox proportional hazards models. RESULTS: Of 109 patients (extrahepatic bile duct resection, n = 34; pancreaticoduodenectomy, n = 75), extrahepatic bile duct resection was associated with a lower incidence of major complications (5.9% vs 45.3%, P < .01) and shorter hospitalization (11 vs 25 days, P < .01). However, extrahepatic bile duct resection was associated with significantly worse 5-year overall survival (38.9% vs 60.4%) and recurrence-free survival (31.7% vs 57.4%) compared with pancreaticoduodenectomy (both P < .01). Multivariate analysis identified extrahepatic bile duct resection and T2 stage as independent predictors of poor overall survival and recurrence-free survival. In patients with negative margin, extrahepatic bile duct resection was associated with worse 5-year overall survival (51.2% vs 61.6%, P = .051) and recurrence-free survival (37.3% vs 59.9%, P = .022) and higher local recurrence (38.1% vs 11.6%, P < .01). CONCLUSION: Despite lower perioperative morbidity, extrahepatic bile duct resection was associated with inferior oncological outcomes compared with pancreaticoduodenectomy, even in early stage extrahepatic cholangiocarcinoma. Pancreaticoduodenectomy should be considered the standard surgical procedure whenever feasible. Although extrahepatic bile duct resection should not be regarded as oncologically equivalent to pancreaticoduodenectomy, it may remain a treatment option for carefully selected patients who are unable to tolerate pancreaticoduodenectomy.
引用
- Murase Y, Aikawa M, Oba T, et al. Safety and long-term outcomes of extrahepatic bile duct resection for early stage extrahepatic cholangiocarcinoma: Comparison with pancreaticoduodenectomy. Surgery. 2026. PMID: 42468138. doi:10.1016/j.surg.2026.110420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。